Brisbane-based ALS does lab testing with 19,000 staff in over 70 countries.
Its first-half margins were squeezed, partly due to drug testing slowdown.
But shares lifted on positive full-year commentary.
ALS is evaluating its minority stake in troubled European drug research business Nuvisan, contemplating an exit or even taking full control of the asset, after the clinical outsourcing business delivered an unprofitable half.
Shares of ALS rallied on Tuesday on a more upbeat outlook. PHIL CARRICK
Loading...
Liam Walsh writes on investigations and companies with The Australian Financial Review. He has won multiple media awards, worked in Japan and is now based in Brisbane. Email Liam at liam.walsh@afr.com.au
